Cargando…

Editorial: Investigating drugs used off-label in various cancers

Detalles Bibliográficos
Autores principales:	Liu, Wang, Li, Benyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890152/ https://www.ncbi.nlm.nih.gov/pubmed/36741015 http://dx.doi.org/10.3389/fonc.2023.1130834

Ejemplares similares

Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
por: Muniyan, Sakthivel, et al.
Publicado: (2022)

Multiple drugs: Various toxicities, off-label use and no response to off-label therapy: case report
Publicado: (2021)

Multiple drugs: Various toxicities and off-label use: case report
Publicado: (2020)

Multiple drugs: Various toxicites and off-label use: case report
Publicado: (2020)

Multiple drugs: Various toxicities and off-label use: case report
Publicado: (2022)

Characteristics and survival of patients with cancer with intended off-label use—a cohort study
por: Schmitt, Andreas Michael, et al.
Publicado: (2022)

Multiple drugs: Various toxicities and off label use: 3 case reports
Publicado: (2020)

Various drugs: Lack of efficacy following an off-label use: case report
Publicado: (2021)

Multiple drugs: Various toxicities and off label use: 5 case reports
Publicado: (2021)

Multiple drugs: Various toxicities and off-label use: 10 case reports
Publicado: (2021)

Multiple drugs: Various toxicities, off-label use and lack of efficacy: case report
Publicado: (2020)

Multiple drugs: Various toxicities, lack-of-efficacy and off-label use: case report
Publicado: (2021)

Multiple drugs: Various toxicities, off-label use and lack of efficacy: case report
Publicado: (2022)

Multiple drugs: Various toxicities with lack of efficacy and off label use: case report
Publicado: (2022)

Off-Label Use of Thrombopoietin Receptor Agonists: Case Series and Review of the Literature
por: Capecchi, Marco, et al.
Publicado: (2021)

Multiple drugs: Various toxicities, off-label use, and drug overdose due to drug interaction: case report
Publicado: (2020)

Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
por: Huang, Jian, et al.
Publicado: (2022)

Jumonji domain-containing protein RIOX2 is overexpressed and associated with worse survival outcomes in prostate cancers
por: He, Chenchen, et al.
Publicado: (2023)

TMEM158 expression is negatively regulated by AR signaling and associated with favorite survival outcomes in prostate cancers
por: Huang, Jian, et al.
Publicado: (2022)

Dexamethasone: Various toxicities and off-label use: case report
Publicado: (2022)

Multiple drugs: Various toxicities following off-label use and lack-of-efficacy: case report
Publicado: (2021)

Multiple drugs: Lack of efficacy, and various toxicities due to off-label use: case report
Publicado: (2022)

Multiple drugs: Various toxicities, and lack of efficacy following off-label use: case report
Publicado: (2022)

Fluvoxamine/theophylline: Various toxicities following drug interaction and off-label use: case report
Publicado: (2022)

Multiple drugs: Various reactions, lack of efficacy and off-label use: 2 case reports
Publicado: (2022)

Hepcidin Downregulation Correlates With Disease Aggressiveness And Immune Infiltration in Liver Cancers
por: Wang, Jinhu, et al.
Publicado: (2021)

Multiple drugs: Various toxicities, lack of efficacy, off-label use and drug interactions: 4 case reports
Publicado: (2022)

Alternol/Alteronol: Potent Anti-cancer Compounds With Multiple Mechanistic Actions
por: Liu, Wang, et al.
Publicado: (2020)

Editorial: Therapeutic drug monitoring and clinical toxicology of anti-cancer drugs
por: Liu, Yao, et al.
Publicado: (2022)

Multiple drugs: Various toxicities following interaction and off-label: 2 case reports
Publicado: (2020)

Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use—Patient Harms and Prescriber Responsibilities
por: Van Norman, Gail A.
Publicado: (2023)

Recommendations on Off-Label Drug Use in Pediatric Guidelines
por: Meng, Min, et al.
Publicado: (2022)

Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China
por: WANG, Weilan, et al.
Publicado: (2013)

Editorial: The effect of anti-cancer drug therapies in the treatment of lung cancer
por: Pisapia, Pasquale, et al.
Publicado: (2022)

Editorial: Therapeutic drug monitoring and clinical toxicology of anti-cancer drugs, volume II
por: Yan, Miao, et al.
Publicado: (2023)

Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
por: Fischler, Pascal Valentin, et al.
Publicado: (2022)

Multiple drugs: Various toxicities, lack of efficacy following off label use and vaccine failure: case report
Publicado: (2022)

Tocilizumab: Various toxicities following an off-label use: 3 case reports
Publicado: (2020)

Hydroxychloroquine: Various toxicities secondary to off label use: 3 case reports
Publicado: (2020)

Tocilizumab: Various toxicities following off label use: 4 case reports
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6qfrlo5cn813apu7k3g1kiq9a9